PDA's newly revised PDA Technical Report No. 56, Revised 2016 Application of Phase-Appropriate Quality System and cGMP to the Development of Therapeutic Protein Drug Substance provides an overview of the ideal state for broad good manufacturing practices (GMPs) throughout the product lifecycle and as they become more stringent from the discovery/R&D stage through Phase 3 clinical trials to commercial launch. This report also describes a basic framework for clinical trial manufacturing for sites where full commercial development and/or manufacturing may not be the organizational goal (e.g., university/grant-funded investigators, start-up biotech firms).
More Standards PDF
PIP PCCTE001
$50.00 $100.00
PIP ELSMC14D
$25.00 $50.00
PIP PN03CS1B01
$37.00 $75.00
PIP RESE001-D-EEDS
$25.00 $50.00